Average Co-Inventor Count = 3.82
ph-index = 12
The patent ph-index is calculated by counting the number of publications for which an author has been cited by other authors at least that same number of times.
Company Filing History:
1. Bristol-myers Squibb Compnay (48 from 3,685 patents)
2. Compound Therapeutics, Inc. (2 from 6 patents)
3. Bristol Meyers Squibb Company (1 from 41 patents)
4. Celexion, LLC (1 from 10 patents)
5. Aktis Oncology, Inc. (1 from 1 patent)
53 patents:
1. 12427212 - Nectin-4 binding miniproteins, conjugates and uses thereof
2. 12247058 - Nucleic acids encoding modified FGF-21 polypeptides, vectors and cells containing, and use thereof
3. 12194110 - PD-L1 binding polypeptides for imaging
4. 12097241 - Methods of treating kidney failure, and/or improving or stablizing renal function using modified relaxin polypeptides
5. 12097242 - Treatment of fibrosis, cardiovascular disease and heart failure with modified relaxin polypeptides
6. 11913137 - Methods for the selection of binding proteins
7. 11858979 - Fibronectin based scaffold domain proteins that bind PCSK9
8. 11813315 - Fibronectin based scaffold domain proteins that bind to myostatin
9. 11524992 - Glypican-3-binding fibronectin based scaffold molecules
10. 11447538 - Fibronectin based scaffold proteins
11. 11434275 - Fast-off rate serum albumin binding fibronectin type III domains
12. 11408093 - Fibronectin binding domains with reduced immunogenicity
13. 11407815 - Stabilized fibronectin based scaffold molecules
14. 11364281 - Modified relaxin polypeptides comprising a pharmacokinetic enhancer and pharmaceutical compositions thereof
15. 11344639 - PET imaging with PD-L1 binding polypeptides